文献类型：期刊文献

英文题名：3B, a novel photosensitizer, inhibits glycolysis and inflammation via miR-155-5p and breaks the JAK/STAT3/SOCS1 feedback loop in human breast cancer cells

作者：Lei, Kecheng[1,2];Du, Wenpei[1,2];Lin, Shengchao[1,2];Yang, Liyan[1,2];Xu, Yichun[1,2];Gao, Yuwei[1,2];Xu, Baixue[1,2];Tan, Shaoying[3];Xu, Yufang[3];Qian, Xuhong[3];Liang, Xin[1,2];Liu, Jianwen[1,2]

机构：[1]East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai, Peoples R China;[2]East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai, Peoples R China;[3]East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab Chem Biol, State Key Lab Bioreactor Engn, Shanghai, Peoples R China

年份：2016

卷号：82

起止页码：141

外文期刊名：BIOMEDICINE & PHARMACOTHERAPY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000381679000019)】；

基金：This work was supported by Shanghai Committee of Science and Technology (No. 13140902300), the Shanghai Committee of Science and Technology [grant 11DZ2260600] and Science-technology Support Project of Shanghai (No. 13401900502)

语种：英文

外文关键词：PDT; miR-155; Glycolysis; Inflammation

摘要：Compared to normal cells, most cancer cells produce ATP by glycolysis under aerobic conditions rather than via the tricarboxylic acid cycle (TCA). This study is intended to determine whether 3B, a novel photosensitizer, can inhibit glycolysis and inflammation in breast cancer cells. We showed that 3B had the ability to repress glucose consumption as well as the generation of ATP, lactate and lactate dehydrogenase. 3B-PDT not only inhibited the expression of IL-1 beta and IL-6 but also affected the JAK-STAT3 inflammatory pathway in vitro. The present study showed that 3B featured a significant inhibitory effect on the expression of microRNA-155-5p and SOCS1 might serve as a target gene. In vivo studies revealed that 3B inhibited tumor growth and exhibited almost no side effects. Therefore, through the anti-glycolytic effect and breakage of the JAK/STAT3/SOCS1 feedback loop via miR-155-5p, 3B may potentially serve as a potential therapeutic agent against breast cancer. (C) 2016 Elsevier Masson SAS. All rights reserved.